July 9, 2026

The Cardiology Department at CHU Rouen is among the first centers in Europe to adopt the Valvosoft® technology following its CE marking.
 
Valvosoft® is an innovative non-invasive therapy intended to treat patients suffering from symptomatic severe Aortic valve stenosis who are not recommended for an immediate Aortic valve replacement. This non-invasive solution allows the Heart Team to consider additional options for the lifetime management of Aortic valve stenosis.
 
At CHU Rouen, Dr. @Thibaut Hémery has successfully performed twelve Valvosoft® procedures, treating patients coming from across France as well as coming from other countries. 
 
Thank you to the team at CHU de Rouen for their trust and commitment to advancing new treatment options for these patients.

Read CHU Rouen’s Linkedin post here: https://www.linkedin.com/feed/update/urn:li:activity:7480908745448005632
 
@Service de cardiologie du CHU de Rouen @Hélène Eltchaninoff  @Eric Durand #Cardiawave #Valvosoft @CHU de Rouen
#Cardiology #LifetimeManagementofAorticStenosis#HeartTeam #Innovation #MedTech #RHU Stop AS